<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03904199</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-19637</org_study_id>
    <nct_id>NCT03904199</nct_id>
  </id_info>
  <brief_title>Prospective Study of Personalized Approach to Inpatient Patients With Hyperglycemia</brief_title>
  <official_title>A Prospective Randomized Study of a Personalized Approach to the Inpatient Management of Hospitalized Oncology Patients With Hyperglycemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the outcomes between hospitalized cancer patients&#xD;
      with high blood sugar receiving the current standard of care of administering insulin, and&#xD;
      hospitalized cancer patients receiving a new, individualized method of insulin&#xD;
      administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Anticipated">April 3, 2022</completion_date>
  <primary_completion_date type="Actual">October 14, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of blood glucose values within normal range</measure>
    <time_frame>During hospital admission, up to 30 days</time_frame>
    <description>Proportion of blood glucose values in the 70 mg/dL to 180 mg/dL (normal) range</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of high blood glucose levels</measure>
    <time_frame>During hospital admission, up to 30 days</time_frame>
    <description>Proportion of blood glucose values &gt;180 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of low blood glucose levels</measure>
    <time_frame>During hospital admission, up to 30 days</time_frame>
    <description>Proportion of blood glucose values &lt;70 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of normal blood glucose level</measure>
    <time_frame>During hospital admission, up to 30 days</time_frame>
    <description>Duration of blood glucose values in the 70 mg/dL to 180 mg/dL (normal) range</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Basal-Prandial-Correctional Insulin Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants hospitalized in the medical, hematologic, or bone marrow transplant units will begin with basal long-acting insulin glargine with correctional and prandial rapid-acting insulin that is personalized and precise, to achieve target blood glucose levels with daily assessments during hospitalization. Adjustments will be made in real time to reach the target range.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care Insulin Regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants hospitalized in the medical, hematologic, or bone marrow transplant units' blood sugar levels will be managed with sliding scale insulin or a combination of long- and short-acting insulin as per standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Participants will receive long-acting insulin and/or rapid-acting insulin per protocol</description>
    <arm_group_label>Basal-Prandial-Correctional Insulin Regimen</arm_group_label>
    <arm_group_label>Standard of Care Insulin Regimen</arm_group_label>
    <other_name>Basal insulin</other_name>
    <other_name>Prandial insulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of signed and dated informed consent form&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Provide race and ethnicity information&#xD;
&#xD;
          -  Male or female, aged 18 years or greater&#xD;
&#xD;
          -  Diagnosed with cancer&#xD;
&#xD;
          -  Hospitalized at MCC in the medical, hematologic, or bone marrow transplant units&#xD;
&#xD;
          -  Having in-hospital hyperglycemia with or without a pre-existing diagnosis of DM, with&#xD;
             2 measurements of BG &gt; 180 mg/dL and/or 1 measurement of BG &gt; 350mg/dL within the&#xD;
             first 72 hours of admission, detected by bedside point-of-care testing and/or basic&#xD;
             metabolic panel laboratory data.&#xD;
&#xD;
          -  Participants enrolled in other clinical trials are admissible to this trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  An individual who meets any of the following criteria will be excluded from&#xD;
             participation in this study:&#xD;
&#xD;
          -  Participants &lt; 18 years of age&#xD;
&#xD;
          -  Participants at the end of life and/or with limited life expectancies (&lt; 6 months)&#xD;
&#xD;
          -  Participants without cancer diagnoses&#xD;
&#xD;
          -  Surgical patients and patients admitted directly to the intensive care unit, other&#xD;
             than those in the Bone Marrow Transplant Unit, who are included&#xD;
&#xD;
          -  Participants treated and discharged in outpatient settings (ie, direct referral&#xD;
             center, infusion center, or clinical research unit) or those admitted for observation&#xD;
             only (hospitalized less than 24 hours)&#xD;
&#xD;
          -  Participants on total parenteral nutrition&#xD;
&#xD;
          -  Participants on insulin pumps&#xD;
&#xD;
          -  Participants admitted with diabetic ketoacidosis and hyperglycemic hyperosmolar&#xD;
             syndrome&#xD;
&#xD;
          -  Pregnant Participants based on medical history&#xD;
&#xD;
          -  Participants being followed by endocrinology for hyperglycemia or hypoglycemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Smitha Pabbathi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High Blood Sugar</keyword>
  <keyword>High Blood Glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

